On the surface, potato chips and memory chips seem to be moving in opposite directions. AI has created a vereniging of demand for micro‑processors, even as chipmaker stocks have been knocked down. In contrast, the widespread use of GLP‑1 weight‑loss drugs threatens the future of crisp snacks.

A study in the *American Journal of Clinical Nutrition* found that users of Wegovy and Zepbound cut calories by 24‑30%, which could reduce overall food demand by at least 5% if a fifth of the world takes the drugs. Processed foods would্ব hit hardest; a McKinsey report citing a Cornell study showed that after six months on the jabs, patients spent 11.5% less on potato chips and other savory snacks.

That explains why U.S. food and beverage shares have slipped. Pepsi’s valuation fell from 23 times earnings to just 16, even as earnings grow. Utz’s price dropped about half after Intersnack paid a 91% premium. Other snack names—Kellogg, Kellanova and Tree House Foods—were taken private by Ferrero, Mars and Investindustrial, hoping to cut costsેબ.

In tech, forecasting is harder than ever. SK Hynix’s shares trade at less than 3 times projected earnings two years out, despite a recent price fall. Both chip sectors face uncertainty that could erode their long‑term moats.